Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04056611 · ClinicalTrials.gov registry record · Phase 2
Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)
A Phase 2 study, sponsored by Janssen Sciences Ireland UC.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT04056611: Clinical Trial Phase 2 study, sponsored by Janssen Sciences Ireland UC.
NCT04056611 is a Phase 2 study that was terminated before completion, run by Janssen Sciences Ireland UC. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04056611, a Phase 2 study, was terminated before completion, sponsored by Janssen Sciences Ireland UC.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of JNJ-53718678 on the development of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTIs) in adult hematopoietic stem cell transplant (HSCT) recipients with RSV upper RTI.
Primary Outcome
Percentage of participants who developed RSV LRTI was assessed. RSV LRTI was defined as the development of a lower respiratory sign or symptom (including decrease in oxygen saturation or increase in supplemental oxygen to maintain oxygen saturation, wheezing, rhonchi, rales, dyspnea, tachypnea, worsening cough) and positive RSV test from lower respiratory tract sample (example \[eg\], sputum, induced sputum, bronchoalveolar lavage (BAL), lung biopsy, or autopsy specimen) within +-4 days of a new
Interventions
- DRUG Placebo
- DRUG JNJ-53718678 250 mg
- DRUG JNJ-53718678 125 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-12-26 |
| Est. Completion | 2022-02-04 |
| Phase | Phase 2 |
Why NCT04056611 stopped before completion
NCT04056611 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04056611 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04056611 about?
NCT04056611 is a clinical study titled "Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)". The purpose of this study is to evaluate the effect of JNJ-53718678 on the development of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTIs) in adult hematopoietic stem cell transplant (HSCT) recipients with RSV upper RTI.
What is the current status of trial NCT04056611?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2019-12-26. Estimated completion is 2022-02-04.
What interventions are being tested in trial NCT04056611?
The interventions under investigation include: Placebo (DRUG), JNJ-53718678 250 mg (DRUG), JNJ-53718678 125 mg (DRUG).
Who is sponsoring clinical trial NCT04056611?
This trial is sponsored by Janssen Sciences Ireland UC, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04056611's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI